Imaging features and low disability distinguished a nonacute myelin oligodendrocyte glycoprotein antibody-positive cohort from MS and AQP4 Ab+ cohorts with high accuracy.
Myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD) is being increasingly recognized. MOGAD signs and symptoms can overlap with those of multiple sclerosis (MS) and aquaporin-4 antibody (AQP4 Ab+) disease (NEJM JW Neurol Oct 27 2020 and Ann Neurol 2021; 89:30; NEJM JW Neurol Dec 13 2022 and Neurology 2023; 100:e308). In this multicenter, retrospective study, investigators sought to classify patients as having MS (189), AQP4 (162), or MOG (162) based on clinical and imaging features, using a Random Forest test for discriminators.
Nonacute MOGAD diagnosis was associated with younger age, low disability, low number of brain lesions (<6), absence of Dawson's fingers, absence of temporal lobe lesions, absence of cortical lesi…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)